3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Glioblastoma
6
Neuroblastoma
5
Central Nervous System Neoplasms
5
Gliosarcoma
4
Medulloblastoma
3
Glioma
3
Brain Neoplasms
3
Sarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Pinealoma
2
Ependymoma
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Pyloric Stenosis, Hypertrophic
1
Osteosarcoma
1
Oligodendroglioma
1
Neurofibromatosis 1
1
Neurofibroma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Histiocytosis, Langerhans-Cell
1
Carcinoma
1
Brainstem Glioma
1
Astrocytoma
1
Interventions
Cyclophosphamide
8
Temozolomide
6
Topotecan
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
X-Rays
4
Phantoms, Imaging
4
Irinotecan
4
palbociclib
3
fludarabine
3
Vincristine
3
Specimen Handling
3
Sirolimus
3
Magnetic Resonance Spectroscopy
3
Busulfan
3
Bone Marrow Transplantation
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
ivosidenib
2
irinotecan sucrosofate
2
cabozantinib
2
abemaciclib
2
Zoledronic Acid
2
Vemurafenib
2
Nuclear Medicine Department, Hospital
2
Nivolumab
2
Mesna
2
LY3023414
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Ewing
×
Celecoxib
×
CNS
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled